title: [Severe hyponatraemia secondary to cure of cyclophosphamide (about three cases)].
authors.forename: M
authors.initials: M
authors.lastname: Alilou
authors.forename: A
authors.initials: A
authors.lastname: Awab
authors.forename: M
authors.initials: M
authors.lastname: Zarouf
authors.forename: R El
authors.initials: RE
authors.lastname: Moussaoui
authors.forename: A El
authors.initials: AE
authors.lastname: Hijri
authors.forename: A
authors.initials: A
authors.lastname: Azzouzi
authors.forename: A
authors.initials: A
authors.lastname: Slaoui
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000150:complications; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced* / Q000188:drug therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007177:Inappropriate ADH Syndrome / Q000139:chemically induced; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004232:Diuretics; D007166:Immunosuppressive Agents; D005665:Furosemide; D003520:Cyclophosphamide